TScan Therapeutics to Participate in Upcoming Investor Conferences
WALTHAM, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq:TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that management will participate in the following upcoming investor conferences:
Related news for (TCRX)
- TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
- TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access
- TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
- 24/7 Market News Snapshot 26 December, 2024 – TScan Therapeutics, Inc. Common Stock (NASDAQ:TCRX)
- TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium